Fosun Health Capital

The firm leverages Fosun International's physical presence in over 30 countries to offer portfolio companies rapid access to the Chinese healthcare market — including public hospital tenders, retail pharmacy distribution, and regulatory pathway navigation. It also provides manufacturing scale-up capabilities via Fosun's domestic pharmaceutical and device production infrastructure. This industrial backing differentiates it from purely financial venture capital firms.

The firm invests primarily in China, the United States, Europe, and Israel. Its mandate includes accessing innovations developed in Western markets and commercializing them within China and other Fosun operational geographies. Notable cross-border deals include the acquisition of Gland Pharma in India and Ambrx in the United States.

Fosun Health Capital operates as a direct investment platform under Fosun International, while Fosun Pharma is a separately listed subsidiary focused on pharmaceutical R&D and manufacturing. The two entities coordinate strategically: Fosun Health Capital often acquires assets that later integrate with or supply Fosun Pharma's pipeline and distribution network. This creates a proprietary funnel from venture-stage innovation to scaled commercial production.

Yes. The firm is structured to execute both minority growth investments and majority buyouts. Its parent balance sheet allows it to lead rounds and acquire controlling interests when the strategic fit — particularly market-access synergies — justifies ownership. Deals like Alma Lasers and Luz Saúde exemplify this consolidation approach.

The firm predominantly deploys direct capital but has historically participated in club-style deals and joint ventures — particularly when navigating new geographic or therapeutic territories. Given its parent's balance-sheet heft, Fosun Health Capital often acts as a lead or sole investor rather than a passive LP in third-party funds.